Skip to main content Accessibility help
×
Home

Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects

  • A. Greyling (a1), C De Witt (a1), W Oosthuizen (a1) and J. C. Jerling (a1)

Abstract

Policosanol is a mixture of higher aliphatic primary alcohols that is extracted from purified sugar cane wax or a variety of other plant sources, and has been shown to have beneficial effects on serum lipid concentrations. The objective of this study was to investigate the effects of a policosanol supplement (Octa-60) on lipid profiles of hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects. Nineteen hypercholesterolaemic and familial hypercholesterolaemic subjects completed this randomised, placebo-controlled, double-blind study. The subjects received either a daily dose of 20 mg policosanol or placebo for 12 weeks. After a wash-out period of 4 weeks, the interventions were crossed over. Lipid levels were measured at baseline and at the end of each intervention period. No significant differences in total cholesterol and LDL-cholesterol from baseline to end or between policosanol and placebo were seen in the hypercholesterolaemic or familial hypercholesterolaemic groups. There were small reductions in total cholesterol and LDL-cholesterol from baseline to end in the hypercholesterolaemic group, but these changes did not differ significantly from the changes with the placebo, indicating that the observed decrease in cholesterol in the policosanol group was not due to the specific effect of policosanol treatment. The differences in response may be ascribed to the differences in composition of the higher aliphatic primary alcohols in the previously used products, compared with the local policosanol supplement. An intake of 20 mg/d policosanol for 12 weeks had no significant effect on serum lipid levels in hypercholesterolaemic and heterozygous familial hypercholesterolaemic patients when compared with placebo intake.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects
      Available formats
      ×

Copyright

Corresponding author

*Corresponding author: Professor J. C. Jerling, fax +27 18 299 2464, email vgejcj@puk.ac.za

References

Hide All
Aleman, CL, Castanome>Mas, R, Hernandez, C, Rodeiro, I, Cerejido, E, Noa, M, Capote, A, Menendez, R, Amor, A & Fraga, VA 12-month study of policosanol oral toxicity in Sprague Dawley rats Toxicol Lett 1994 70, 7787.
Aleman, CL, Puig, MN, Elias, EC, Ortega, CH, Guerra, IR, Ferreiro, RM & Brinis, FCarcinogenicity of policosanol in mice: an 18-month study. Food Chem Toxicol. 1995 33 573578.
Aneiros, E, Mas, R, Calderon, B, Illnait, J, Fernandez, L, Castano, G & Fernandez, JCEffect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res 1995 56, 176182.
Arruzazabala, ML, Carbajal, D, Mas, R, Molina, V, Valdes, S & Laguna, ACholesterol-lowering effects of policosanol in rabbits. Biol Res 1994 27, 205208.
Batista, J, Stusser, R, Saez, F & Perez, BEffect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients.A 14-month pilot study. Int J Clin Pharmacol Ther 1996 34, 134137.
Benitez, M, Romero, C, Mas, R, Fernandez, L & Fernandez, JCA comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia. Curr Ther Res 1997 58, 859867.
Canetti, MM, Moreira, M, Mas, R, Illnait, J, Fernandez, L & Fernandez, JCEffects of policosanol on primary hypercholesterolemia:a 3-year open-extension follow-up. Curr Ther Res. 1997 58, 868875.
Canetti, M, Moreira, M, Mas, R, Illnait, J, Fernandez, L, Fernandez, J, Diaz, E & Castano, GA two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Int J Clin Pharmacol Res 1995 15, 159165.
Castano, G, Canetti, M, Moreira, M, Tula, L, Mas, R, Illnait, J, Fernandez, L, Fernandez, JC & Diaz, EEfficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: a 12-month study. Curr Ther Res 1995a 56, 819828.
Castano, G, Fernandez, L, Mas, R, Illnait, J, Fernandez, J, Mesa, M, Alvarez, E & Lezcay, MComparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia. Int J Clin Pharmacol Res 2002a 22, 5566.
Castano, G, Fernandez, L, Mas, R, Illnait, J, Mesa, M & Fernandez, JCComparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. Clin Drug Invest 2003a 23, 639650.
Castano, G, Mas, R, Arruzazabala, ML, Noa, M, Illnait, J, Fernandez, JC, Molina, V & Menendez, Affects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res 1999a 19, 105116.
Castano, G, Mas, R, Cesar Fernandez, J, Pontigas, V, Suazo, M & Fernandez, LOpen-label study of the efficacy, safety, and tolerability of policosanol in patients with high global coronary risk. Curr Ther Res 1998 59, 737745.
Castano, G, Mas, R, Fernandez, JC, Fernandez, L, Alvarez, E & Lezcay, MEfficacy and tolerability of policosanol compared with lovastatin in patients with type II hypercholesterolemia and concomitant coronary risk factors. Curr Ther Res 2000a 61, 137146.
Castano, G, Mas, R, Fernandez, JC, Fernandez, L, Illnait, J & Lopez, EEffects of policosanol on older patients with hypertension and type II hypercholesterolaemia. Drugs RD 2002b 3, 159172.
Castano, G, Mas, R, Fernandez, L, Fernandez, JC, Illnait, J, Lopez, LE & Alvarez, EEffects of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 2000b 14, 187195.
Castano, G, Mas, R, Fernandez, JC & Illnait, JComparative effects of two once-daily regimens of policosanol in patients with type II hypercholesterolemia. Curr Ther Res 1997 58, 154162.
Castano, G, Mas, R, Fernandez, JC, Illnait, J, Fernandez, L & Alvarez, EEffects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol A Biol Sci Med Sci 2001a 56, M186M192.
Castano, G, Mas, R, Fernandez, L, Illnait, J, Gamez, R & Alvarez, EEffects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. Int J Clin Pharmacol Res 2001b 21, 4357.
Castano, G, Mas, R, Fernandez, L, Illnait, J, Gamez, R & Fernandez, JCComparison of two regimens of policosanol administered at 20 mg/d in patients with type II hypercholesterolemia: a randomized, double-blind, placebo-controlled study. Curr Ther Res 2001c 62, 194208.
Castano, G, Mas, R, Fernandez, L, Illnait, J, Hernandez, E, Fernandez, JC, Gamez, R, Gutierrez, C & Alvarez, EA randomized, double-blind, placebo-controlled study of the efficacy and tolerability of policosanol in adolescents with type II hypercholesterolemia. Curr Ther Res 2002c 63, 286303.
Castano, G, Mas, R, Fernandez, L, Illnait, J, Mesa, M, Alvarez, E & Lezcay, MComparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. Drugs Aging 2003b 20, 153163.
Castano, G, Mas, R, Fernandez, JC, Lopez, LE & Fernandez, LA long-term, open-label study of the efficacy and tolerability of policosanol in patients with high global coronary risk. Curr Ther Res 1999b 60, 379391.
Castano, G, Mas, R, Fernandez, J, Lopez, E, Illnait, J, Fernandez, L & Mesa, MEffects of policosanol on borderline to mildly elevated serum total cholesterol levels: a prospective, doubleblind, placebo-controlled, parallel-group, comparative study. Curr Ther Res 2003c 64, 522537.
Castano, G, Mas, R, Nodarse, M, Illnait, J, Fernandez, L & Fernandez, JCOne-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia. Curr Ther Res 1995b 56, 296304.
Castano, G, Menendez, R, Mas, R, Amor, A, Fernandez, JL, Gonzalez, RL, Lezcay, M & Alvarez, EEffects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. Int J Clin Pharmacol Res 2002d 22, 8999.
Castano, G, Tula, L, Canetti, M, Morera, M, Mas, R, Illnait, J, Fernandez, L & Fernandez, JCEffects of policosanol in hypertensive patients with type II hypercholesterolemia. Curr Ther Res 1996 57, 691699.
Civeira, FGuidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004 173, 5568.
Crespo, N, Alvarez, R, Mas, R, Illnait, J, Fernandez, L & Fernandez, JCffects of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: a pilot study. Curr Ther Res 1997 58, 4451.
Crespo, N, Illnait, J, Mas, R, Fernandez, L, Fernandez, J & Castano, GComparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus.. Int J Clin Pharmacol Res 1999 19, 117127.
Fernandez, JC, Mas, R, Castano, G, Menendez, R, Amor, AM, Gonzalez, RM & Alvarez, EComparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolaemic women. Clin Drug Investig 2001 21, 103113.
Fernandez, L, Mas, R, Illnait, J & Fernandez, JC, Policosanol: results of a postmarketing surveillance study of 27,879 patients. Curr Ther Res 1998 59, 717722.
Friedewald, WT, Levy, RI & Fredrickson, DSEstimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 18, 499502.
Gamez, R, Aleman, CL, Mas, R, Noa, M, Rodeiro, I, Garcia, H, Hernandez, C, Menendez, R & Aguilar, CA 6-month study on the toxicity of high doses of policosanol orally administered to Sprague-Dawley rats. J Med Food 2001 4, 5765.
Gouni-Berthold, I & Berthold, HKPolicosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002 143, 356365.
Hargrove, JL, Greenspan, P & Hartle, DKNutritional signifi-cance and metabolism of very long chain fatty alcohols and acids from dietary waxes. Exp Biol Med (Maywood) 2004 229, 215226.
Janikula, MPolicosanol: a new treatment for cardiovascular disease?. Altern Med Rev 2002 7, 203217.
Lin, Y, Rudrum, M, van der Wielen, RP, Trautwein, EA, McNeill, G, Sierksma, A & Meijer, GWWheat germ policosanol failed to lower plasma cholesterol in subjects with normal to mildly elevated cholesterol concentrations. Metabolism 2004 53, 13091314.
McNamara, DJCardiovascular disease.In:Modern nutrition in healthand disease.pp.15331544 [Shils, ME, Olson, JA and Shike, Meditors]. Philodelphia: Lea and Febiger. 1994
Marcello, S, Gladstein, J, Tesone, P & Mas, REffects of bezafi- brate plus policosanol or placebo in patients with combined dyslipidemia: a pilot study. Curr Ther Res 2000 61, 346357.
Margetts, B & Nelson, MDesign Concepts in Nutritional Epidemiology,2nd edn. Oxford: Oxford University Press. 1997
Mas, RPolicosanol. Hypolipidemic antioxidant treatment of atherosclerosis. Drugs Future 2000 25, 569586.
Mas, R, Castano, G, Fernandez, L, Illnait, J, Fernandez, J & Alvarez, EEffects of policosanol on lipid profile and cardiac events in older hypercholesterolaemic patients with coronary disease. Clin Drug Invest 2001 21, 485497.
Mas, R, Castano, G, Illnait, J, Fernandez, L, Fernandez, J, Aleman, C, Pontigas, V & Lescay, MEffects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1999a 65, 439447.
Mas, R, Rivas, P, Izquierdo, JE, Hernandez, R, Fernandez, L, Fernandez, J, Orta, SD, Illnait, J & Ricardo, YPharmacoepidemiologic study of policosanol. Curr Ther Res 1999b 60, 458467.
Menendez, R, Amor, AM, Gonzalez, RM, Fraga, V & Mas, REffect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats. Biol Res 1996 29, 253257.
Menendez, R, Amor, AM, Rodeiro, I, Gonzalez, RM, Gonzalez, PC, Alfonso, JL & Mas, RPolicosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch Med Res 2001 32, 812.
Menendez, R, Arruzazabala, L, Mas, R.et al. Cholesterollowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet. Br J Nutr 1997 77, 923932.
Menendez, R, Fernandez, SI, Del Rio, A, Gonzalez, RM, Fraga, V, Amor, AM & Mas, RMPolicosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res 1994 27, 199203.
Mirkin, A, Mas, R, Martinto, M, Boccanera, R, .et al. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women. Int J Clin Pharmacol Res 2001 21, 3141.
Murphy, KJ, Saint, DA & Howe, PRLack of effect of sugar cane and sunflower seed policosanols on plasma cholesterol in rabbits. Asia Pac J Clin Nutr 2004 13, S69.
Ortensi, G, Julio, G, Hector, V & Pedro, ATA comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res 1997 58, 390401.
Pappu, AS & Illingworth, DRThe effects of lovastatin and simvastatin on the diurnal periodicity of plasma mevalonate concentrations in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2002 165, 137144.
Pons, P, Illnait, J, Mas, R, Rodriguez, M, Aleman, C, Cesar Fernandez, J, Fernandez, L & Martin, Mcomparative study of policosanol versus probucol in patients with hypercholesterolemia. Curr Ther Res 1997 58, 2635.
Pons, P, Rodriguez, M, Robaina, C, Illnait, J, Mas, R, Fernandez, L & Fernandez, JCEffects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res 1994 14, 2733.
Rodriguez, MD & Garcia, HTeratogenic and reproductive studies of policosanol in the rat and rabbit. Teratog Carcinog Mutagen 1994 14, 107113.
Rodriguez, MD & Garcia, HEvaluation of peri- and post-natal toxicity of Policosanol in rats. Teratog Carcinog Mutagen 1998 18, 17.
Rodriguez-Echenique, C, Mesa, R, Mas, R, Noa, M, Menendez, R, Gonzalez, RM, Amor, AM, Fraga, V, Sotolongo, V & Laguna, AEffects of policosanol chronically administered in male monkeys (Macaca arctoides). Food Chem Toxicol 1994 32, 565575.
Sauvage Nolting, PR, Defesche, JC, Buirma, RJ, Hutten, BA, Lansberg, PJ & Kastelein, JJPrevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med 2003 253, 161168.
Siavoshian, S, Simoneau, C, Maugeais, P, Marks, L, Rodary, L, Gardette, J & Krempf, MMeasurement of mevalonic acid in human urine by bench top gas chromatography-mass spectrometry. Clin Chim Acta 1995 243, 129136.
Torres, O, Agramonte, AJ, Illnait, J, Mas Ferreiro, R, Fernandez, L & Fernandez, JCTreatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 397 1995 18, 393.
Varady, KA, Wang, Y & Jones, PJHRole of policosanols in the prevention and treatment of cardiovascular disease. Nutr Rev 2003 61, 376383.
Wang, YW, Jones, PJH, Pischel, I & Fairow, CEffects of policosanols and phytosterols on lipid levels and cholesterol biosynthesis in hamsters. Lipids 2003 38, 165170.

Keywords

Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects

  • A. Greyling (a1), C De Witt (a1), W Oosthuizen (a1) and J. C. Jerling (a1)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed